Related Experiment Video
Updated: Jun 21, 2026
Substernal Thyroid Biopsy Using Endobronchial Ultrasound-guided Transbronchial Needle Aspiration
Published on: November 10, 2014
Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations
I Garcia-Olivé1, E Monsó, F Andreo
1Servei de Pneumologia, Hospital Germans Trias i Pujol, Carretera de Canyet s/n, 08916 Badalona, Spain. ignasi.g.olive@gmail.com
Abstract:
The presence of somatic mutations of the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene in patients with advanced nonsmall cell lung cancer (NSCLC) correlates with a good response to tyrosine kinase inhibitors. The usefulness of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for the detection of EGFR mutations in cells recovered from malignant mediastinal nodes in patients with NSCLC was assessed. All patients with lung adenocarcinoma or unspecified NSCLC referred for staging with EBUS-TBNA were included. Nodes with a short-axis diameter of >5 mm were sampled, and genomic DNA from metastatic tumour cells was obtained for analysis of exons 19 and 21. The impact of sampling on management was assessed. EGFR gene analysis of the EBUS-TBNA sample was feasible in 26 (72.2%) out of the 36 patients with lymph node metastasis. Somatic mutations of the EGFR gene were detected in tissue obtained through EBUS-TBNA in two (10%) out of 20 patients with metastasic lung adenocarcinoma. Malignant tissue samples obtained by EBUS-TBNA from patients with nodal metastasis of NSCLC are suitable for the detection of EGFR mutations in most cases, and this technique demonstrates mutated neoplastic cells in a tenth of patients with adenocarcinoma.
Insights
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) effectively detects epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) patients. This technique is suitable for analyzing mediastinal nodes, aiding in targeted therapy selection for NSCLC.
Area of Science:
- Oncology
- Pulmonology
- Molecular Diagnostics
Background:
- Somatic mutations in the epidermal growth factor receptor (EGFR) gene are crucial biomarkers in advanced non-small cell lung cancer (NSCLC).
- These mutations predict a favorable response to tyrosine kinase inhibitors (TKIs), a cornerstone of targeted therapy.
- Accurate and timely detection of these mutations is essential for patient management.
Purpose of the Study:
- To evaluate the utility of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for detecting EGFR mutations.
- To assess the feasibility of analyzing genomic DNA from mediastinal lymph node samples obtained via EBUS-TBNA in NSCLC patients.
- To determine the diagnostic yield of EBUS-TBNA for EGFR mutation analysis in NSCLC with nodal metastasis.
Main Methods:
- Prospective study including NSCLC patients referred for mediastinal staging via EBUS-TBNA.
- Sampling of mediastinal lymph nodes with a short-axis diameter >5 mm.
- Genomic DNA extraction and analysis of EGFR exons 19 and 21 from metastatic tumor cells.
Main Results:
- EGFR gene analysis was feasible in 72.2% (26/36) of patients with lymph node metastasis.
- Somatic EGFR mutations were detected in 10% (2/20) of patients with metastatic lung adenocarcinoma.
- EBUS-TBNA successfully identified mutated neoplastic cells in a subset of NSCLC patients with nodal metastasis.
Conclusions:
- EBUS-TBNA is a valuable tool for obtaining malignant tissue samples from mediastinal nodes in NSCLC.
- The technique is suitable for EGFR mutation detection, facilitating personalized treatment strategies.
- EBUS-TBNA provides a minimally invasive method for molecular profiling in NSCLC staging.
